JP3614479B2 - Periodontal disease-causing bacteria or caries-causing bacteria inhibitor, oral composition and food containing them - Google Patents

Periodontal disease-causing bacteria or caries-causing bacteria inhibitor, oral composition and food containing them Download PDF

Info

Publication number
JP3614479B2
JP3614479B2 JP27637094A JP27637094A JP3614479B2 JP 3614479 B2 JP3614479 B2 JP 3614479B2 JP 27637094 A JP27637094 A JP 27637094A JP 27637094 A JP27637094 A JP 27637094A JP 3614479 B2 JP3614479 B2 JP 3614479B2
Authority
JP
Japan
Prior art keywords
periodontal disease
oil
causing bacteria
farnesol
suppression agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP27637094A
Other languages
Japanese (ja)
Other versions
JPH07316064A (en
Inventor
條二 山原
晶子 三木
陽子 山口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morishita Jintan Co Ltd
Original Assignee
Morishita Jintan Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morishita Jintan Co Ltd filed Critical Morishita Jintan Co Ltd
Priority to JP27637094A priority Critical patent/JP3614479B2/en
Publication of JPH07316064A publication Critical patent/JPH07316064A/en
Application granted granted Critical
Publication of JP3614479B2 publication Critical patent/JP3614479B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Confectionery (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

【0001】
【産業上の利用分野】
本発明は歯周病原因菌又はう蝕原因菌の両者に有効に抑制作用を有する歯周病原因菌又はう蝕原因菌抑制剤に関する。また本発明は上記の歯周病原因菌又はう蝕原因菌抑制剤を含有する口腔用組成物及び食品に関する。
【0002】
【従来の技術及び発明が解決しようとする課題】
歯周病は外傷性のものを除き、ある種の菌が歯牙や歯周組織に付着、定着し、それらの菌が産生する酵素や内毒素が歯周組織を破壊することにより生じると考えられている。これらの菌としては、ポルフィロモナス(Porphyromonas)菌群、フゾバクテリウム ヌクレイタム(Fusobacteriumnucleatum)等のグラム陰性偏性嫌気性桿菌があり、歯周病患者の病巣ではこれらの菌の増殖が認められる。したがって歯周病を予防、治療するためには、これらの菌の成育を押えることが重要であり、歯周病原因菌に対して有効な抗菌活性物質の開発が望まれている。
【0003】
従来、歯周病の予防及び治療用の薬剤としては、前記菌を殺菌するための抗生物質や合成した抗菌剤(例えば、クロルヘキシジン、セチルピリジニウム等)が提案されている。しかし前者の抗生物質については、副作用の問題や口腔内の正常細菌叢を乱し「菌交代症」を起こす可能性が指摘されており、またグラム陰性偏性嫌気性桿菌に有効なものが少ないため、実用的ではない。また後者の合成抗菌剤は、人体への安全性も問題となる。
このため、抗菌活性物質は安全性の高い天然物であることが望ましい。
【0004】
一方、う蝕の原因については、これまで種々の仮説が提唱されてきたが現在では細菌感染症の一種であると認められておりその発生機構も明らかになりつつある。
う蝕の発生の原因になる細菌は、ストレプトコッカスミュータンス(Streptococcus mutans)、ストレプトコッカスソブリヌス(Streptococcus sobrinus)等の口腔レンサ球菌である。これらの細菌は、口腔内に於て食物由来のショ糖を基質とし水不溶性、粘着性のある多糖であるグルカンを生成する。生成されたグルカンは、う蝕原因菌と共に歯の表面に付着して歯垢を形成する。さらにその歯垢中で細菌は糖を代謝し有機酸を生成する。この酸が歯のエナメル質を脱灰し、う蝕が発生すると考えられている。
【0005】
したがってう蝕を予防するためには、(1)抗生物質などでストレプトコッカスミュータンスをはじめとする口腔レンサ球菌を殺菌する、(2)細菌の歯面への付着防止などの手段で歯垢形成を抑える、(3)歯垢形成を促すような食物(ショ糖)をとらない等の方法が考えられる。
【0006】
しかしながら、食物からショ糖を完全に除去することは不可能であり、また抗生物質による口腔内細菌の殺菌についても前述したように、副作用の問題や、口腔内の正常細菌叢を乱し、「菌交代症」をおこす可能性が指摘されていることから有効には採用され得ない。
【0007】
従って、本発明は安全性が高くしかも、歯周病原因菌とう蝕原因菌の両者に有効な抑制作用を示し、歯周病を予防、治療すると共にう蝕原因菌の歯面への付着を抑制し、歯垢の形成を防止する薬剤を提供することを目的とする。
【0008】
【課題を解決するための手段】
本発明は、新たにファルネソール及びファルネサールが歯周病原因菌に対する有効な抗菌活性物質であると共に、う蝕原因菌の歯面への付着を抑制するという発見に基づいている。
即ち、本発明はファルネソール又はファルネサールを含有する歯周病原因菌又はう蝕原因菌抑制剤を提供する。
尚、本明細書において、「抑制作用」とは歯周病原因菌又はう蝕原因菌の成長の抑制のみならず、殺菌或は増殖の防止を含む広い概念で用いられる。「抑制剤」とは抑制作用を果すように用いる薬剤をいい、予防剤、治療剤の概念も包含する。
【0009】
ファルネソールはプチグレン油、シトロネラ油、ネロリ油、アンブレット油、レモングラス油、ローズ油、カブルバ油、及び菩提樹花油等の天然植物油に含まれる無色油状物質で、古くから花香調の調合香料や、オリエンタル、シプレー調の調合香料として使用されてきた。また、アプリコット、バナナ、ピーチ、メロン、ストロベリー等の食品のフレーバーにも使用されている。
【0010】
ファルネソールは式:
【化2】

Figure 0003614479
で表されるものの中でRが−CHOHのものを(3,7,11−トリメチル−2,6,10−ドデカトリエン−1−オール)いう。このファルネソールは、公知の合成方法を用いて生成してもよい。例えば、イソプレンを出発原料にし、このイソプレンと塩酸を反応させてプレニルクロライドを得る。次いでプレニルクロライドとアセトンを反応させてメチルヘプテノンを得、これをロシュ(Roche)法によりリナロールとした後、ジケテンを用いて炭素鎖伸張反応を繰り返してネロリドールを得る。このネロリドールの水酸基を1級アルコールに変換してファルネソールを得る。この反応は合成が容易で比較的安価に行うことができる。
【0011】
ファルネサールは式:
【化3】
Figure 0003614479
で表されるものの中でRが−CHOのものを(3,7,11−トリメチル−2,6,10−ドデカトリエン−1−アール)いう。即ちファルネサールは前記ファルネソールの酸化体であり、前記ファルネソールと共に天然植物油に含まれている。
【0012】
また、ファルネサールを、例えば、前述のファルネソール合成の途中で得られたネロリドールを酸化することによって得ることができる。
【0013】
ファルネソール及びファルネサールは、これらを含有する天然植物油の精油をそのまま、又はエタノール等で希釈して本発明の抑制剤に適用してもよいが、歯周組織又は歯の表面への到達性、残留性の点から、他の適当な添加剤を含有させて口腔用組成物、例えばハミガキ剤、洗口剤の形に製剤化して抑制剤とするのが好ましい。このような添加剤としては、乳化剤(レシチン、ソルビタンモノオレート等)、乳化助剤(ソルビットシロップ、メチルセルロース、ゼラチン等)、その他酸化防止剤、着色剤、香料等を含有することができる。
【0014】
ファルネソール又はファルネサールの配合量は口腔用組成物全体に対して、約0.01〜10重量%、好ましくは0.1〜1重量%配合される。
【0015】
本発明者らは、ファルネソール及びファルネサールにチョウジ油、ウイキョウ油、甘茶抽出エキスから選択される少なくとも1種を添加した混合物が非常に強く歯垢の付着を抑制することを見いだしており、特に好ましい。
チョウジ油、ウイキョウ油、又は甘茶抽出エキスを含有する場合には、ファルネソール又はファルネサール、及びチョウジ油、ウイキョウ油、又は甘茶抽出エキスの配合量はそれぞれ口腔用組成物全体に対して、約0.01〜10重量%、好ましくは約0.1〜1重量%配合される。
【0016】
また、本発明の歯周病原因菌又はう蝕原因菌抑制剤をチューインガム、キャンディー等の食品に適用することができる。
食品に適用する場合には本発明の抑制剤は食品に対して、約0.1〜1重量%の量配合される。
【0017】
【発明の効果】
本発明によれば、歯周病原因菌に対して優れた抗菌活性を示すとともにう蝕原因菌の歯面への付着を阻害して歯垢の形成を抑制することができる歯周病原因菌又はう蝕原因菌抑制剤を提供することができる。
本発明の抑制剤は、天然物に由来するので人体への投与に関して非常に安全である。
本発明の抑制剤は天然物に由来するのでチューインガム、キャンディーなどの食品に安全に適用することができる。
【0018】
【実施例】
本発明を以下の実施例により更に詳細に説明する。
(実施例1;抗歯周病性試験)
(供試菌液の調製)
▲1▼ ポルフィロモナス ジンジバリス(Porphyromonas gingivalis)GAI7802
▲2▼ フゾバクテリウム ヌクレイタム(Fusobacterium nucleatum)IID891
▲3▼ プレボテラ インターミディア(Prevotella intermedia)ATCC25611
▲4▼ カプノサイトロファーガ スプティゲナ(Capnocytophaga sputigena)ATCC33612
▲5▼ バクテロイデス メラニノゲニカス(Bacteroides melaninogenicus)GIFU4637上記▲1▼〜▲5▼菌株をヘミン(シグマ社製)及びメナジオン(和光純薬社製)添加のGAM寒天培地(GAMブイヨン(日水製薬製)に細菌培地用寒天末(和光純薬製)を1%添加したもの)で、37℃、72時間嫌気培養した(三菱ガス化学製アネロパックシステムを使用)。培養により生じたコロニーをGAMブイヨン培地に接種し、▲1▼及び▲2▼の菌株は72時間、▲3▼及び▲5▼の菌株は48時間、▲4▼の菌株は24時間、37℃で嫌気培養後、更にGAMブイヨン培地に植え継ぎ、37℃で24時間嫌気培養した。培養後、吸光度を0.3(610nm)に調製し、生理食塩水で1/100に希釈して供試菌液とした。
【0019】
(歯周病原因菌に対する抗菌活性試験)
ファルネソール又はファルネサールの濃度を適宜変化させたジメチルスルホキシド溶液を調製し、歯周病抑制剤とした。
前記供試菌液100μlと、前記各歯周病抑制剤100μlをGAMブイヨン培地10mlに接種し、37℃で24〜72時間嫌気培養した。培養後、菌の発育の有無を目視観察し、完全に発育が阻止された培地中に含まれるファルネソール及びファルネサールの最低濃度を最小発育阻止濃度とした。その結果を表1に示す。
【0020】
【表1】
Figure 0003614479
【0021】
上記結果よりファルネソール及びファルネサールは非常に少量で歯周病原因菌に対して抗菌活性を示すことがわかる。
【0022】
(実施例2;抗う蝕性試験)
試験管内での歯垢形成抑制試験を次の方法で行った。
ストレプトコッカス ソブリヌス(Streptococcus sobrinus )GIFU8819をブレインハート インフュージョン培地(DIFCO社製 以下BHI培地と略称する)で37℃,24時間培養した。
ショ糖5%を含むBHI培地3mlに、ジメチルスルホキシド(DMSO)溶液としたファルネソール又はファルネサールを含有する試料を所定濃度となるように添加し、これに前培養しておいた菌液100μlを植菌した。これを水平面に対して30度の角度に傾け、37℃,3日間培養した後、培養液を捨て蒸留水で2回洗浄後、試験管壁に付着した歯垢を90℃で乾燥し、歯垢形成量を測定した。結果を表2に示す。
また、グルカン形成時にう蝕菌によって糖が代謝され有機酸が産生することにより培地が酸性となることから、培養液のpHも測定した。結果を表3に示す。表中、ミックスオイルとは、ファルネソール、チョウジ油、ウイキョウ油、甘茶抽出エキスの混合物のことである。その混合比はチョウジ油3.0、ウイキョウ油1.0、ファルネソール2.0、甘茶抽出エキス0.3、である。
また、ショ糖のかわりに歯垢付着抑制効果のあるパラチノースを5%添加したものを対照とした。
【0023】
【表2】
Figure 0003614479
【0024】
【表3】
Figure 0003614479
上記結果よりファルネソール,ファルネサールが優れた歯垢付着抑制効果を有することが認められた。
【0025】
(実施例3)
薬用歯磨き剤に製剤化したファルネソール又はファルネサールを含有する歯周病原因菌又はう蝕原因菌抑制剤を例示する。
Figure 0003614479
【0026】
(実施例4)
洗口液に製剤化したファルネソール又はファルネサールを含有する歯周病原因菌又はう蝕原因菌抑制剤を例示する。
Figure 0003614479
【0027】
(実施例5)
トローチに製剤化したファルネソール又はファルネサールを含有する歯周病原因菌又はう蝕原因菌抑制剤を例示する。
Figure 0003614479
【0028】
(実施例6)
歯周病原因菌又はう蝕原因菌抑制剤のチュ−インガムへの適用を例示する。
Figure 0003614479
【0029】
(実施例7)
歯周病原因菌又はう蝕原因菌抑制剤の飴への適用を例示する。
Figure 0003614479
【0030】
(実施例8)
歯周病原因菌又はう蝕原因菌抑制剤のアイスクリームへの適用を例示する。
Figure 0003614479
[0001]
[Industrial application fields]
The present invention relates to a periodontal disease-causing fungus or a caries-causing fungus inhibitor that has an effective inhibitory effect on both periodontal disease-causing bacteria or caries-causing bacteria. Moreover, this invention relates to the composition for oral cavity and foodstuff containing said periodontal disease cause microbe or a caries cause microbe inhibitor.
[0002]
[Prior art and problems to be solved by the invention]
Periodontal disease, except for traumatic diseases, is thought to be caused by certain bacteria attached to and fixed on teeth and periodontal tissues, and the enzymes and endotoxins produced by these bacteria destroy periodontal tissues. ing. Examples of these bacteria include Gram-negative anaerobic bacilli such as the Porphyromonas group and Fusobacterium nucleatum, and the growth of these bacteria is observed in the foci of periodontal disease patients. Therefore, in order to prevent and treat periodontal disease, it is important to suppress the growth of these bacteria, and development of an antibacterial active substance effective against periodontal disease-causing bacteria is desired.
[0003]
Conventionally, as a drug for preventing and treating periodontal diseases, antibiotics for sterilizing the bacteria and synthesized antibacterial agents (for example, chlorhexidine, cetylpyridinium, etc.) have been proposed. However, it has been pointed out that the former antibiotics have problems of side effects and may disrupt the normal bacterial flora in the oral cavity, resulting in “mycosis”, and few are effective against Gram-negative obligate anaerobic bacilli Therefore, it is not practical. The latter synthetic antibacterial agent also has a problem with safety to the human body.
For this reason, it is desirable that the antibacterial active substance is a highly safe natural product.
[0004]
On the other hand, various hypotheses have been proposed for the cause of caries, but now it is recognized as a kind of bacterial infection and its mechanism of development is becoming clear.
Bacteria causing the occurrence of caries are oral streptococci such as Streptococcus mutans and Streptococcus sobrinus. These bacteria produce glucan, which is a water-insoluble and sticky polysaccharide in the oral cavity using sucrose derived from food as a substrate. The generated glucan adheres to the tooth surface together with caries-causing bacteria to form plaque. In addition, bacteria in the plaque metabolize sugar to produce organic acids. This acid is thought to decalcify the tooth enamel and cause caries.
[0005]
Therefore, in order to prevent caries, (1) sterilize oral streptococci such as Streptococcus mutans with antibiotics, etc. (2) prevent plaque formation by means such as prevention of bacterial adhesion to the tooth surface. (3) A method of not taking food (sucrose) that promotes plaque formation is conceivable.
[0006]
However, it is impossible to completely remove sucrose from food. Also, as mentioned above, sterilization of oral bacteria with antibiotics disturbs the problem of side effects and normal bacterial flora in the oral cavity. Since it has been pointed out the possibility of causing "mycosis", it cannot be used effectively.
[0007]
Therefore, the present invention is highly safe and exhibits an effective inhibitory action on both periodontal disease-causing bacteria and caries-causing bacteria, preventing and treating periodontal disease and preventing caries-causing bacteria from adhering to the tooth surface. It aims at providing the chemical | medical agent which suppresses and prevents the formation of plaque.
[0008]
[Means for Solving the Problems]
The present invention is based on the discovery that farnesol and farnesal are newly effective antibacterial active substances against periodontal disease-causing bacteria and suppress the adhesion of caries-causing bacteria to the tooth surface.
That is, the present invention provides a periodontal disease-causing or caries-causing fungus inhibitor containing farnesol or farnesal.
In the present specification, the term “suppressing action” is used in a broad concept including not only suppression of growth of periodontal disease-causing bacteria or caries-causing bacteria but also sterilization or prevention of proliferation. “Inhibitor” refers to a drug used to exert an inhibitory action, and includes the concept of a preventive agent and a therapeutic agent.
[0009]
Farnesol is a colorless oily substance contained in natural vegetable oils such as petitgren oil, citronella oil, neroli oil, amblet oil, lemongrass oil, rose oil, cabruba oil, and linden tree flower oil. It has been used as an oriental and syplayy blended fragrance. It is also used in flavors of foods such as apricot, banana, peach, melon and strawberry.
[0010]
Farnesol has the formula:
[Chemical formula 2]
Figure 0003614479
In which R is —CH 2 OH (3,7,11-trimethyl-2,6,10-dodecatrien-1-ol). This farnesol may be produced using a known synthesis method. For example, isoprene is used as a starting material, and this isoprene is reacted with hydrochloric acid to obtain prenyl chloride. Next, prenyl chloride and acetone are reacted to obtain methylheptenone, which is converted into linalool by the Roche method, and then carbon chain extension reaction is repeated using diketene to obtain nerolidol. Farnesol is obtained by converting the hydroxyl group of this nerolidol into a primary alcohol. This reaction is easy to synthesize and can be performed relatively inexpensively.
[0011]
Farnesal has the formula:
[Chemical 3]
Figure 0003614479
In which R is —CHO (3,7,11-trimethyl-2,6,10-dodecatrien-1-al). That is, farnesal is an oxidized form of the farnesol and is contained in the natural vegetable oil together with the farnesol.
[0012]
Further, farnesal can be obtained, for example, by oxidizing nerolidol obtained during the aforementioned synthesis of farnesol.
[0013]
Farnesol and farnesal may be applied to the inhibitor of the present invention as they are or by diluting natural vegetable oils containing them as they are with ethanol or the like, but reachability to the periodontal tissue or tooth surface, persistence From this point, it is preferable that other appropriate additives are contained and formulated into oral compositions such as toothpastes and mouthwashes to form inhibitors. Such additives can contain emulsifiers (lecithin, sorbitan monooleate, etc.), emulsification aids (sorbite syrup, methylcellulose, gelatin, etc.), other antioxidants, colorants, fragrances and the like.
[0014]
The amount of farnesol or farnesal blended is about 0.01 to 10% by weight, preferably 0.1 to 1% by weight, based on the whole oral composition.
[0015]
The present inventors have found that a mixture obtained by adding at least one selected from clove oil, fennel oil, and sweet tea extract to farnesol and farnesal very strongly suppresses adhesion of plaque, and is particularly preferable.
When clove oil, fennel oil, or sweet tea extract is contained, the blending amount of farnesol or farnesal and clove oil, fennel oil, or sweet tea extract is about 0.01 with respect to the whole oral composition. -10 wt%, preferably about 0.1-1 wt%.
[0016]
The periodontal disease-causing bacteria or caries-causing bacteria inhibitor of the present invention can be applied to foods such as chewing gum and candy.
When applied to food, the inhibitor of the present invention is blended in an amount of about 0.1 to 1% by weight based on the food.
[0017]
【The invention's effect】
According to the present invention, a periodontal disease-causing bacterium that exhibits excellent antibacterial activity against periodontal disease-causing bacteria and can inhibit the formation of dental plaque by inhibiting the caries-causing bacteria from attaching to the tooth surface. Or the caries cause microbe inhibitor can be provided.
Since the inhibitor of the present invention is derived from a natural product, it is very safe for administration to the human body.
Since the inhibitor of the present invention is derived from natural products, it can be safely applied to foods such as chewing gum and candy.
[0018]
【Example】
The invention is illustrated in more detail by the following examples.
(Example 1: Anti-periodontal disease test)
(Preparation of test bacteria solution)
(1) Porphyromonas gingivalis GAI7802
(2) Fusobacterium nucleatum IID891
(3) Prevotella intermedia ATCC25611
(4) Capnocytophaga sputigena ATCC 33612
(5) Bacteroides melaninogenicus (Bacteroides melaninogenicus) GIFFU4637 The above strains (1) to (5) were added to GAM agar medium (GAM bouillon (manufactured by Nissui Pharmaceutical)) supplemented with hemin (manufactured by Sigma) and menadione (manufactured by Wako Pure Chemical Industries). Bacterial culture medium agar powder (made by Wako Pure Chemical Industries, 1%) was anaerobically cultured at 37 ° C. for 72 hours (using Mitsubishi Gas Chemical's Aneropack system). Colonies generated by the culture were inoculated into GAM broth medium, 72 hours for strains (1) and (2), 48 hours for strains (3) and (5), 24 hours for strain (4), 37 ° C. After anaerobic culture, the cells were further transplanted to a GAM broth medium and anaerobically cultured at 37 ° C. for 24 hours. After culturing, the absorbance was adjusted to 0.3 (610 nm) and diluted to 1/100 with physiological saline to obtain a test bacterial solution.
[0019]
(Antimicrobial activity test against periodontal disease-causing bacteria)
A dimethyl sulfoxide solution in which the concentration of farnesol or farnesal was appropriately changed was prepared and used as a periodontal disease inhibitor.
100 μl of the test bacterial solution and 100 μl of each periodontal disease inhibitor were inoculated into 10 ml of GAM bouillon medium and anaerobically cultured at 37 ° C. for 24-72 hours. After the culture, the presence or absence of the growth of the bacteria was visually observed, and the minimum concentration of farnesol and farnesal contained in the medium in which the growth was completely inhibited was defined as the minimum growth inhibition concentration. The results are shown in Table 1.
[0020]
[Table 1]
Figure 0003614479
[0021]
From the above results, it can be seen that farnesol and farnesal exhibit antibacterial activity against periodontal disease-causing bacteria in very small amounts.
[0022]
Example 2 Anti-Caries Test
The plaque formation suppression test in the test tube was performed by the following method.
Streptococcus sobrinus GIFU8819 was cultured in a brain heart infusion medium (manufactured by DIFCO, hereinafter abbreviated as BHI medium) at 37 ° C. for 24 hours.
A sample containing farnesol or farnesal in a dimethyl sulfoxide (DMSO) solution was added to 3 ml of a BHI medium containing 5% sucrose to a predetermined concentration, and 100 μl of a precultured bacterial solution was inoculated thereto. did. This was tilted at an angle of 30 degrees with respect to the horizontal plane, and cultured at 37 ° C for 3 days. After discarding the culture solution and washing twice with distilled water, the plaque adhering to the test tube wall was dried at 90 ° C, The amount of plaque formation was measured. The results are shown in Table 2.
In addition, since the medium was acidic due to sugar metabolism and organic acid production by caries bacteria during glucan formation, the pH of the culture solution was also measured. The results are shown in Table 3. In the table, mixed oil refers to a mixture of farnesol, clove oil, fennel oil, and sweet tea extract. The mixing ratio is clove oil 3.0, fennel oil 1.0, farnesol 2.0, sweet tea extract 0.3.
In addition, 5% palatinose having an effect of suppressing plaque adhesion was added instead of sucrose as a control.
[0023]
[Table 2]
Figure 0003614479
[0024]
[Table 3]
Figure 0003614479
From the above results, it was confirmed that farnesol and farnesal had an excellent plaque adhesion inhibitory effect.
[0025]
(Example 3)
Examples include periodontal disease-causing bacteria or caries-causing bacteria inhibitors containing farnesol or farnesal formulated into a medicated dentifrice.
Figure 0003614479
[0026]
(Example 4)
Examples include periodontal disease-causing bacteria or caries-causing bacteria inhibitors containing farnesol or farnesal formulated in a mouthwash.
Figure 0003614479
[0027]
(Example 5)
Examples include periodontal disease-causing bacteria or caries-causing bacteria inhibitors containing farnesol or farnesal formulated in a troche.
Figure 0003614479
[0028]
(Example 6)
The application of the periodontal disease-causing bacteria or caries-causing bacteria inhibitor to chewing gum is exemplified.
Figure 0003614479
[0029]
(Example 7)
An example of application of a periodontal disease-causing bacteria or a caries-causing fungus inhibitor to sputum is illustrated.
Figure 0003614479
[0030]
(Example 8)
The application to the ice cream of the periodontal disease causative bacteria or the caries causative bacteria inhibitor is illustrated.
Figure 0003614479

Claims (9)

式:
Figure 0003614479
(式中、Rは−CH2OH、又は−CHOである)で表されるファルネソール又はファルネサールを含有する歯周病原因菌抑制剤。
formula:
Figure 0003614479
(Wherein, R -CH 2 OH, or a is -CHO) periodontal disease-causing bacteria suppression agent containing farnesol or farnesal represented by.
前記ファルネソールがプチグレン油、シトロネラ油、ネロリ油、アンブレット油、レモングラス油、ローズ油、カブルバ油、及び菩提樹花油からなる群から選択される1以上の油から得られたものである請求項1記載の歯周病原因菌抑制剤。The farnesol is obtained from one or more oils selected from the group consisting of petitgren oil, citronella oil, neroli oil, ambret oil, lemongrass oil, rose oil, cabruba oil, and linden tree flower oil. periodontal disease-causing bacteria suppression agent as claimed 1. 前記ファルネソール又はファルネサールを0.01〜10重量%含有する請求項1記載の歯周病原因菌抑制剤。Periodontal disease-causing bacteria suppression agent according to claim 1 containing 0.01 to 10 wt% of the farnesol or farnesal. 前記ファルネソール又はファルネサールを0.1〜1重量%含有する請求項1記載の歯周病原因菌抑制剤。Periodontal disease-causing bacteria suppression agent according to claim 1 containing 0.1 to 1 wt% of the farnesol or farnesal. 更にチョウジ油、ウイキョウ油、及び甘茶抽出エキスから選択される少なくとも1種を含有する請求項1記載の歯周病原因菌抑制剤。Furthermore clove oil, fennel oil, and periodontal disease-causing bacteria suppression agent according to claim 1, further comprising at least one selected from Hydrangeae Dulcis Folium extract. 前記ファルネソール又はファルネサールを0.1〜1重量%、チョウジ油、ウイキョウ油、及び甘茶抽出エキスから選択される少なくとも1種を約0.1〜10重量%含有する請求項5記載の歯周病原因菌抑制剤。The cause of periodontal disease according to claim 5, comprising 0.1 to 1% by weight of the farnesol or farnesal, and about 0.1 to 10% by weight of at least one selected from clove oil, fennel oil, and sweet tea extract. bacteria suppression agent. 請求項1〜6のいずれか記載の歯周病原因菌抑制剤を含有する口腔用組成物。Periodontal disease-causing bacteria suppression agent oral compositions containing according to any of claims 1 to 6. 請求項1〜6のいずれか記載の歯周病原因菌抑制剤を含有する食品。Periodontal disease-causing bacteria food containing suppression agent according to any of claims 1 to 6. 前記歯周病原因菌抑制剤を0.1〜1重量%含有する請求項8記載の食品。Food according to claim 8 containing 0.1 to 1% by weight of the periodontal disease-causing bacteria suppression agent.
JP27637094A 1993-11-10 1994-11-10 Periodontal disease-causing bacteria or caries-causing bacteria inhibitor, oral composition and food containing them Expired - Lifetime JP3614479B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP27637094A JP3614479B2 (en) 1993-11-10 1994-11-10 Periodontal disease-causing bacteria or caries-causing bacteria inhibitor, oral composition and food containing them

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP28105093 1993-11-10
JP6-58580 1994-03-29
JP5858094 1994-03-29
JP5-281050 1994-03-29
JP27637094A JP3614479B2 (en) 1993-11-10 1994-11-10 Periodontal disease-causing bacteria or caries-causing bacteria inhibitor, oral composition and food containing them

Publications (2)

Publication Number Publication Date
JPH07316064A JPH07316064A (en) 1995-12-05
JP3614479B2 true JP3614479B2 (en) 2005-01-26

Family

ID=27296628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP27637094A Expired - Lifetime JP3614479B2 (en) 1993-11-10 1994-11-10 Periodontal disease-causing bacteria or caries-causing bacteria inhibitor, oral composition and food containing them

Country Status (1)

Country Link
JP (1) JP3614479B2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3615894B2 (en) * 1997-01-20 2005-02-02 株式会社ノエビア Antibacterial hypoallergenic cosmetic
JPH10203954A (en) * 1997-01-20 1998-08-04 Noevir Co Ltd Antimicrobial low-irritating cosmetic
US6248309B1 (en) 1997-04-04 2001-06-19 Optiva Corporation Gums containing antimicrobial agents
JP2000512660A (en) * 1997-04-04 2000-09-26 オプティバ・コーポレーション Antimicrobial agents for oral hygiene products
ATE272397T1 (en) * 1999-04-22 2004-08-15 Shiseido Co Ltd SELECTIVE ANTIBACTERIAL COMPOSITIONS
GB2359746A (en) * 2000-01-06 2001-09-05 Mars Uk Ltd Antibacterial agents
GB2357967A (en) * 2000-01-06 2001-07-11 Mars Uk Ltd Antibacterial agents
JP2002104983A (en) * 2000-09-28 2002-04-10 Kobayashi Pharmaceut Co Ltd Anticariogenic agent
JP3877537B2 (en) * 2001-03-07 2007-02-07 高砂香料工業株式会社 Antibacterial agent for oral composition and oral composition containing the same
JP4691320B2 (en) * 2003-12-26 2011-06-01 株式会社資生堂 Composition for inhibiting fat accumulation
JP2005200339A (en) * 2004-01-15 2005-07-28 Takuo Sakai Antimicrobial agent
JP2006199661A (en) * 2005-01-24 2006-08-03 Sunstar Inc Coaggregation inhibitor
US9591852B2 (en) 2009-11-23 2017-03-14 Mcneil-Ppc, Inc. Biofilm disruptive compositions
JP7290906B2 (en) * 2015-02-13 2023-06-14 ロート製薬株式会社 Periodontal ligament regeneration agent and method for producing the same
JP6886174B2 (en) * 2017-01-31 2021-06-16 株式会社東洋新薬 Oral composition for oral care

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3014128B2 (en) * 1990-08-17 2000-02-28 サントリー株式会社 Method for producing anti-cariogenic agent and anti-cariogenic substance
JPH07583B2 (en) * 1990-11-21 1995-01-11 北海道糖業株式会社 Water-soluble pentacyclic triterpene clathrate compound, method for producing the same, and food, beverage and oral composition using the same
JP3241425B2 (en) * 1992-03-13 2001-12-25 サントリー株式会社 Inhibitor of microbial adhesion to animal cells
JP3159509B2 (en) * 1992-03-30 2001-04-23 サンスター株式会社 Protease inhibitor

Also Published As

Publication number Publication date
JPH07316064A (en) 1995-12-05

Similar Documents

Publication Publication Date Title
JP3877537B2 (en) Antibacterial agent for oral composition and oral composition containing the same
JP3614479B2 (en) Periodontal disease-causing bacteria or caries-causing bacteria inhibitor, oral composition and food containing them
EP1649864B1 (en) Periodontal disease therapeutic and/or preventive composition
JPH0140005B2 (en)
JPS61171423A (en) Drug for alleviating dental caries and periodontosis
KR20220107991A (en) Oral composition for prevention or treatment of oral diseases
JP2903210B2 (en) Periodontal disease induction inhibitor composition
JP7445910B2 (en) Oral compositions, oral care products, and foods containing oral resident bacteria regulators
JP3009531B2 (en) Periodontal disease prevention agent
JPH0639375B2 (en) Anti-caries agent
KR101773227B1 (en) Dentrifice composition
JPS61268613A (en) Composition for oral cavity containing evening primrose seed oil
JPS5835484B2 (en) Oral composition
WO2010021370A1 (en) Oral composition
KR20140055885A (en) The gargle composites for the increment of the oral care
JP4515732B2 (en) Glucosyltransferase inhibitors, plaque formation inhibitors, antibacterial agents, oral preparations and foods for preventing touch
KR102452255B1 (en) Composition comprising deacetyl asperulosidic acid and/or asperulosidic acid as active ingredient for prevention or treatment of oral disease
KR20020082308A (en) Composition for the mouth containing extraction of Euonymus alatus Sieb
JPS6258324B2 (en)
JP7362417B2 (en) Growth inhibitors, oral compositions, and promoters of oral pathogenic bacteria
JPH0434968B2 (en)
KR20170094609A (en) Manufactureing method of periodontitis prevention solution
WO2018168821A1 (en) Composition for use in oral cavity
JPH0288518A (en) Composition for oral cavity application
JPS61260017A (en) Composition for oral cavity application having caries-preventive effect

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040706

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040928

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20041027

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071112

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081112

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081112

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091112

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091112

Year of fee payment: 5

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091112

Year of fee payment: 5

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101112

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101112

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111112

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121112

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131112

Year of fee payment: 9

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term